Y-mAbs Faces a 39% Correction as Valuation Diverges From Reality
By stockpickr AI | March 19, 2026 | 10 min read
Investment Summary
Y-mAbs Therapeutics is a commercial-stage biopharmaceutical company focused on developing antibody-based cancer treatments. Sentiment remains cautious.
Investment Recommendation
Sell
Fair Value: $45.13
Current Price: $74.20
Upside/Downside: -39.2%
No recommendation provided
Key Metrics
- Market Cap: $442.15M
- P/E Ratio: N/A
- Dividend Yield: 0.00%
- Analyst Target Price: $10.00
Strengths
- Danyelza commercial momentum in pediatric oncology
- Strong intellectual property portfolio in radioimmunotherapy
- Improved operational efficiency and reduced cash burn
Risk Factors
- High reliance on a narrow product pipeline
- Persistent historical net losses and funding requirements
- Competitive environment in oncology treatments
Latest News
Y-mAbs Therapeutics Provides Corporate Update on Pipeline Progress
Company highlights continued commercial growth for Danyelza and upcoming milestones for clinical candidates.
Source: Yahoo Finance | Sentiment: Moderately Positive